Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Chim Acta. 2018 Feb;477:166-172. doi: 10.1016/j.cca.2017.09.009. Epub 2017 Sep 14.

A facile gold nanoparticle-based ELISA system for detection of osteopontin in saliva: Towards oral cancer diagnostics.

Author information

1
Centre for Nanobiotechnology, VIT University, Vellore, India.
2
Department of Preventive Oncology (Research and Molecular Diagnostics), Cancer Institute (WIA), Chennai, India.
3
Centre for Oral Cancer Prevention Awareness and Research, Sree Balaji Dental College and hospital, Bharath University, Chennai, India.
4
Department of Preventive Oncology (Research and Molecular Diagnostics), Cancer Institute (WIA), Chennai, India. Electronic address: r.vijayalakshmi@cancerinstitutewia.org.
5
Centre for Nanobiotechnology, VIT University, Vellore, India. Electronic address: amitav@vit.ac.in.

Abstract

In the current study, we emphasize that osteopontin is overexpressed in oral squamous cell carcinoma. Overexpression of osteopontin levels was confirmed by mRNA quantification studies and immunohistochemistry analysis. Based on this, a gold nanoparticle-based ELISA system was developed for non-invasive osteopontin detection. The incorporation of AuNRs (Gold nanorods) or AuNSs (Gold nanospheres) in the conventional ELISA improved the sensitivity of analyses. A considerably lowered detection limit in case of AuNR (detection limit: 0.02ngmL-1) and AuNS (detection limit: 0.03ngmL-1) modified assay was obtained as compared to commercially available OPN ELISA kit (detection limit: 0.14ngmL-1). The modified ELISA had a wide linear detection range (0.31-20ngmL-1), good reproducibility, and specificity against the tested interferents in the saliva. Finally, the nanoELISA was validated with osteopontin spiked in artificial and normal saliva samples and observed to show good recovery (95.4-97.85%), which indicates the application potential of the developed kit for real sample analysis.

KEYWORDS:

Gold nanorod; Gold nanosphere; Nano ELISA; Oral cancer; Osteopontin; Sensitivity

PMID:
28917507
DOI:
10.1016/j.cca.2017.09.009
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center